Daiichi Sankyo And GSK Build Japanese Vaccine Firm, While Takeda Expands Abroad
This article was originally published in PharmAsia News
Executive Summary
Both Daiichi Sankyo and Takeda claim to have a path for the top vaccine spot in Japan, but all vaccine firms seem poised to benefit from MHLW's more generous attitude toward preventative medicine.